Dishman Carbogen Amcis (DCAL) reported an 8.1% rise in FY26 revenue to ₹2,931.9 crore, with Profit After Tax witnessing a significant jump. The performance was bolstered by a 200 bps expansion in EBITDA margins to 19.3% and a reduction in net debt. Success in its CDMO segment and high demand for Vitamin D analogues drove top-line growth, signaling progress in the company’s global integrated strategy.
Dishman Carbogen Amcis FY26 Financial Performance
Revenue: ₹2,931.90 Crore | Profit After Tax: ₹97.45 Crore
Reader Takeaway: Strong margin expansion and debt reduction indicate successful operational integration, though French facility ramp-up remains a monitorable bottleneck.
What just happened
Dishman Carbogen Amcis Limited (DCAL) released its financial results for FY2025-26, showing consolidated revenue growth of 8.1% to ₹2,931.90 crore. The company significantly improved its bottom line, with profit after tax rising sharply to ₹97.45 crore compared to ₹3.24 crore in the previous fiscal year. EBITDA also saw a notable 20.6% increase to ₹565.63 crore.
Why this matters
The results highlight the transition of the company from a collection of fragmented global sites into a unified CDMO platform. Improved operating efficiencies and a shift toward higher-value product mixes drove the EBITDA margin to 19.3%, a 200 bps improvement. Furthermore, management continues to prioritize deleveraging, with net debt (excluding lease liabilities) falling to CHF 146.8 million.
Segment Performance
The CDMO business, which accounts for 83% of revenue, benefited from the 'SPRINT' initiative and increased demand for Antibody Drug Conjugates. The Marketable Molecules segment also showed strength, with revenue growing 17.2% and EBITDA margins doubling to 18.8% due to raw material cost optimization.
Risks to watch
Management cited geopolitical tensions as a potential risk factor for logistics and input costs. Additionally, the French facility is seeing a slower-than-expected ramp-up; while not an immediate threat to overall profitability, shareholders should track its path toward break-even in future quarterly updates.
Context metrics
The company currently holds a development pipeline valued at CHF 102 million, with 10 molecules in late Phase III, which provides visibility for upcoming commercial supplies.